The estimated Net Worth of Hayley Lewis is at least 29.3 千$ dollars as of 4 June 2021. Ms Lewis owns over 1,709 units of Zosano Pharma Corp stock worth over 27,876$ and over the last 8 years she sold ZSAN stock worth over 1,384$.
Ms has made over 2 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 1,709 units of ZSAN stock worth 1,384$ on 4 June 2021.
The largest trade she's ever made was buying 4,775 units of Zosano Pharma Corp stock on 19 August 2016 worth over 6,303$. On average, Ms trades about 720 units every 194 days since 2016. As of 4 June 2021 she still owns at least 49,779 units of Zosano Pharma Corp stock.
You can see the complete history of Ms Lewis stock trades at the bottom of the page.
Hayley Lewis is the Sr. VP of Operations at Zosano Pharma Corp.
Ms Lewis is 44, she's been the Sr. VP of Operations of Zosano Pharma Corp since . There are 8 older and no younger executives at Zosano Pharma Corp. The oldest executive at Zosano Pharma Corp is Dr. Donald J. Kellerman, 66, who is the VP of Clinical Devel. & Medical Affairs.
Hayley's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over 5,506,679$ worth of Zosano Pharma Corp stock and bought 790,627 units worth 1,835,090$ . The most active insiders traders include M James Barrett、Enterprise Associates 12, L...、Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of 44,258$. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth 58$.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: